SB455 (2026) Compare Changes


The Bill Text indicates a new section is being inserted. This situation is not handled right now, and the new text is displayed in both the changed and unchanged versions.

Unchanged Version

Text to be removed highlighted in red.

1 New Section; State Medicaid Plan; GLP-1 Medication. Amend RSA 167 by inserting after section 3-m the following new section:

167:3-n State Medicaid Plan; GLP-1 Medication.

I. Medical assistance under the state Medicaid plan shall include coverage for GLP-1 medication if a health care provider licensed in the state of New Hampshire has determined that such medication is medically necessary for the patient and the patient meets one or more of the following:

(a) BMI greater than or equal to 30 kg/m² (obesity); or

(b) BMI greater than or equal to 27 kg/m² with at least one weight-related comorbidity, including:

(1) Type 2 diabetes.

(2) Hypertension.

(3) Dyslipidemia.

(4) Obstructive sleep apnea.

(5) Cardiovascular disease.

(6) Prediabetes.

(7) Metabolic dysfunction associated steatotic liver disease.

II. The department of health and human services shall submit to CMS any amendment to the state Medicaid plan necessary for implementation no later than January 1, 2027.

2 Effective Date. This act shall take effect 60 days after it passage.

Changed Version

Text to be added highlighted in green.

1 New Section; State Medicaid Plan; GLP-1 Medication. Amend RSA 167 by inserting after section 3-m the following new section:

167:3-n State Medicaid Plan; GLP-1 Medication.

I. Medical assistance under the state Medicaid plan shall include coverage for GLP-1 medication if a health care provider licensed in the state of New Hampshire has determined that such medication is medically necessary for the patient and the patient meets one or more of the following:

(a) BMI greater than or equal to 30 kg/m² (obesity); or

(b) BMI greater than or equal to 27 kg/m² with at least one weight-related comorbidity, including:

(1) Type 2 diabetes.

(2) Hypertension.

(3) Dyslipidemia.

(4) Obstructive sleep apnea.

(5) Cardiovascular disease.

(6) Prediabetes.

(7) Metabolic dysfunction associated steatotic liver disease.

II. The department of health and human services shall submit to CMS any amendment to the state Medicaid plan necessary for implementation no later than January 1, 2027.

2 Effective Date. This act shall take effect 60 days after it passage.